Flow cytometry is a technology used in a family of diagnostic tests that combines hydrodynamics and a powerful light source, usually a laser, to isolate and analyze cells of interest.
Clarient said its new PathSite program will provide pathologists with remote access to the instrumentation and software technology needed to effectively analyze specimen data. This access is primarily provided through a web-based portal that allows clients to perform diagnoses and interpretations based on the technical data provided by flow cytometry instruments at Clarient’s laboratory in Irvine, California.
“Advances in cancer management mandate on-line, real-time access to the flow cytometry study, including the report and all of the raw data used by the pathologist,” said Clarient’s chief medical officer Kenneth Bloom. “Access to this detailed information will allow the physicians to carefully monitor and identify subtle changes in a patient’s biological behavior pre- and post-treatment.”
Industry analysts have estimated that the annual flow cytometry market related to cancer testing in the US is $600m.